Moderna argues the F.D.A. should authorize a half-dose of its vaccine as a booster.
By Sharon LaFraniere
Read the full article from The New York Times, here.
Moderna cited the rate of breakthrough infections, “real world evidence of reduced effectiveness against the Delta variant,” and falling levels of neutralizing antibodies from its vaccine six to eight months after a second dose. The company said its clinical trial studies showed that a third injection boosted antibody levels — one measure of the immune system’s response — higher than what they had been before the second dose.